Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 4 , Pages 538-546 , August 2010

Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency

  • Prashanth K. Jayanna, PhD

      Affiliations

    • Department of Pathobiology, Auburn University, Auburn, Alabama, USA
    • ,
  • Deepa Bedi, PhD

      Affiliations

    • Department of Pathobiology, Auburn University, Auburn, Alabama, USA
    • ,
  • James W. Gillespie, BS

      Affiliations

    • Department of Pathobiology, Auburn University, Auburn, Alabama, USA
    • ,
  • Patricia DeInnocentes, BS

      Affiliations

    • Department of Pathobiology, Auburn University, Auburn, Alabama, USA
    • ,
  • Tao Wang, BS

      Affiliations

    • Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA
    • ,
  • Vladimir P. Torchilin, PhD, DSc

      Affiliations

    • Department of Pharmaceutical Sciences, Northeastern University, Boston, Massachusetts, USA
    • ,
  • Richard C. Bird, PhD

      Affiliations

    • Department of Pathobiology, Auburn University, Auburn, Alabama, USA
    • ,
  • Valery A. Petrenko, PhD, DSc

      Affiliations

    • Department of Pathobiology, Auburn University, Auburn, Alabama, USA
    • Corresponding Author InformationCorresponding author: Department of Pathobiology, 252 Greene Hall, Auburn, Alabama 36849, USA.

Received 22 November 2009 ,Accepted 7 January 2010.

References 

  1. Gerber DE. Targeted therapies: a new generation of cancer treatments. Am Fam Physician. 2008;77:311–319
  2. Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res. 2003;9:6567–6571
  3. Lundberg BB. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug Delivery. 2007;14:171–175
  4. Stein R, Qu Z, Cardillo TM, Chen S, Rosario A, Horak ID, et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood. 2004;104:3705–3711
  5. Arap W, Haedicke W, Bernasconi M, Kain R, Rajotte D, Krajewski S, et al. Targeting the prostate for destruction through a vascular address. Proc Natl Acad Sci USA. 2002;99:1527–1531
  6. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, Rio GD, et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med. 1999;5:1032–1038
  7. Ellerby HM, Bredesen DE, Fujimora S, John V. Hunter-killer peptide (HKP) for targeted therapy. J Med Chem. 2008;51:5887–5892
  8. Gerlag DM, Borges E, Tak PP, Ellerby HM, Bredesen DE, Pasqualini R, et al. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. 2001;3:357–361
  9. Kolonin MG, Saha PK, Chan L, Pasqualini R, Arap W. Reversal of obesity by targeted ablation of adipose tissue. Nat Med. 2004;10:625–632
  10. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284
  11. Torchilin VP, Levchenko TS, Lukyanov AN, Khaw BA, Klibanov AL. Rammohan R, et al. p-Nitrophenylcarbonyl-PEG-PE-liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. BBA-Biomembranes. 2001;1511:397–411
  12. Ishida T, Iden DL, Allen TM. A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs. FEBS Lett. 1999;460:129–133
  13. Iden DL, Allen TM. In vitro and in vivo comparison of immunoliposomes made by conventional coupling techniques with those made by a new post-insertion approach. BBA-Biomembranes. 2001;1513:207–216
  14. Kiefer D, Kuhn A. Hydrophobic forces drive spontaneous membrane insertion of the bacteriophage Pf3 coat protein without topological control. EMBO J. 1999;18:6299–6306
  15. Sprujit RB, Wolfs CJAM, Hemminga M. Aggregation-related conformational change of the membrane-associated coat protein of bacteriophage M13. Biochemistry. 1989;28:9158–9165
  16. Jayanna PK, Torchilin VP, Petrenko VA. Liposomes targeted by fusion phage proteins. Nanomed Nanotechnol Biol Med. 2009;5:83–89
  17. Jayanna PK, Deinnocentes P, Bird RC, Petrenko VA. Landscape phage probes for PC3 prostate carcinoma cells. Boston: NSTI Nanotech; 2008;
  18. Brigati JR, Samoylova TI, Jayanna PK, Petrenko VA. Phage display for generating peptide reagents. In:  Coligan JE,  Dunn BM,  Speicher DW,  Wingfield PT editor. Current protocols in protein science. New Jersey: John Wiley and Sons, Inc.; 2008;p. 1–27Unit 18.9
  19. American Cancer Society, Cancer facts and figures - 2009. Atlanta: ACS; 2009;
  20. Chowdhury S, Burbridge S, Harper PG. Chemotherapy for the treatment of hormone-refractory prostate cancer. Int J Clin Pract. 2007;61:2064–2070
  21. Pomerantz M, Kantoff P. Advances in the treatment of prostate cancer. Annu Rev Med. 2007;58:205–220
  22. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer. 2004;112:693–700
  23. Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res. 2007;17:1–14
  24. Elbayoumi TA, Torchilin VP. Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci. 2007;32:159–168
  25. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15:1973–1980
  26. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo 2 L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer. 2005;5:2–9
  27. Soekarjo M, Eisenhawer M, Kuhn A, Vogel H. Thermodynamics of the membrane insertion process of the M13 procoat protein, a lipid bilayer traversing protein containing a leader sequence. Biochemistry. 1996;35:1232–1241
  28. Thiaudiere E, Soekarjo M, Kuchinka E, Kuhn A, Vogel H. Structural characterization of membrane insertion of M13 procoat, M13 coat, and Pf3 coat proteins. Biochemistry. 1993;32:12186–12196
  29. Kuzmicheva GA, Jayanna PK, Sorokulova IB, Petrenko VA. Diversity and censoring of landscape phage libraries. Protein Eng Design Selection. 2009;22:9–18

 This work was supported by National Institutes of Health grants NIH-1 R01 CA125063-01 (to V.A.P.). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute of NIH.

PII: S1549-9634(10)00012-2

doi: 10.1016/j.nano.2010.01.005

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 6, Issue 4 , Pages 538-546 , August 2010

Article Tools

* Image Usage & Resolution